Showing 4161-4170 of 5646 results for "".
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd/2481005/EyePoint Pharmaceuticals, Inc., announced that the first patient has been dosed in the Phase 2 Durasert® and Vorolanib in Ophthalmology 2 (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery antivascular endothelial growth factor (anti-VEGF) treatment for wet
- Lenstec Receives FDA Approval for the SBL-3 Multifocal IOLhttps://modernod.com/news/lenstec-receives-fda-approval-for-sbl-3-multifocal-iol/2481002/Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next-generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensit
- LKC Appoints New Members of Sales and Marketing Leadershiphttps://modernod.com/news/lkc-appoints-new-members-of-sales-and-marketing-leadership/2480999/LKC Technologies, a provider of electroretinography devices, announced the hiring of two industry professionals to lead their strategic efforts to expand its foothold in the US optometric market. Gary VanMatre was appointed Vice President, US Sales, and will lead a geographica
- EyeCare Partners Expands Presence in Virginia with Two Acquisitionshttps://modernod.com/news/eyecare-partners-expands-presence-in-virginia-with-two-acquisitions/2480998/EyeCare Partners (ECP) announced it has entered into an agreement to partner with Commonwealth Eye Care Associates (CECA) and Retina Institute of Virginia (RIV). Financial terms of the deals were not disclosed. Through the partnership with Commonwealth Eye Care Associates, ECP
- Pixium Vision Announces Successful Implantation of First Patient in the Netherlands in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-successful-implantation-of-first-patient-in-the-netherlands-in-prima-system-european-pivotal-trial-primavera/2480993/Pixium Vision announced the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD). This follows approval of the PRIMAvera study by the Dutch Ministry of Health, Welfare and Sport and the open
- RD Fund Announces New Chair and Expansion of Board of Directorshttps://modernod.com/news/rd-fund-announces-new-chair-and-expansion-of-board-of-directors/2480990/The RD Fund (Retinal Degeneration Fund)—the venture arm of the Foundation Fighting Blindness aimed at driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases—announced the appointment of Adrienne Graves, P
- Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-oasis-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480989/Clearside Biomedical announced today completion of dosing in Cohorts 3 and 4 of OASIS, its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicen
- Schwind Eye-Tech Solutions Receives Funding for Laser Surgery Projecthttps://modernod.com/news/schwind-eye-tech-solutions-receives-funding-for-laser-surgery-project/2480987/Schwind eye-tech-solutions announced funding for a new research project aimed at developing an ophthalmic laser system with ultra-short laser pulses[1]. Schwind is planning initial investment in basic research of more than 1.6 million euros, of which around 52% is funding from
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n
- AbbVie and iSTAR Medical Announce Strategic Alliancehttps://modernod.com/news/abbvie-and-istar-medical-announce-strategic-alliance/2480980/AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. The deal gives AbbVie the exclusive right to acquire iST